TCG Labs Soleil Secures $400M Funding, Expands Global R&D Footprint

TCG Labs Soleil, a San Francisco-based venture-biotech firm, has announced a significant $400 million fundraise, matching the size of its inaugural fund from the previous year. This substantial investment is set to bolster the company's ability to advance its biotech portfolio while simultaneously expanding its research and development capabilities on a global scale.

Strategic Focus on Single-Asset Biotechs

The firm's primary focus lies in supporting single-asset biotechs through the critical phase of clinical proof of concept, typically occurring in phase 2 trials. TCG Labs Soleil's unique model aims to position its portfolio companies as attractive candidates for strategic partnerships within the pharmaceutical industry.

Since its inception in 2023, TCG Labs Soleil has demonstrated remarkable growth, establishing more than 10 portfolio companies across various indications and modalities. This diverse approach allows the firm to maintain a broad presence in the biotech landscape while focusing on high-potential programs.

Global Expansion and R&D Enhancement

In a move that underscores its commitment to global reach, TCG Labs Soleil has established a new R&D site in Shanghai. This expansion is part of the company's strategy to create a worldwide network that supports both internally and externally sourced programs, enhancing its ability to identify and develop promising biotech assets.

Peter Svennilson, managing partner at TCG Labs, emphasized the flexibility of their model, stating, "The TCG Labs Soleil model gives us the flexibility and control to invest decisively in the highest-potential single-asset programs, while remaining agile in how and when we engage with biopharma partners."

Recent Strategic Partnerships

The company's global strategy has already begun to bear fruit. In May 2025, Juri Biosciences, a portfolio company of TCG Labs Soleil, entered into a significant licensing agreement with EpimAb Biotherapeutics. The deal, potentially worth up to $210 million, grants Juri Biosciences exclusive rights to EpimAb's T-cell engager designed for the treatment of metastatic prostate cancer.

This partnership exemplifies TCG Labs Soleil's approach to leveraging its portfolio companies to secure strategic collaborations and advance promising therapies through the development pipeline.